Delivery Order SPE2DB20D1100-SPE2DB25FE1H7
- Not listed
- The Defense Logistics Agency awarded a $5,909.37 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (unit dose, 10 count packages) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside award and will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is an acute migraine treatment medication, reflecting the Defense Logistics Agency's...
- The Defense Logistics Agency awarded a delivery order valued at $3,392.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on July 21, 2025, with completion scheduled for July 22, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and is performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.96 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose packages) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,603.68 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (100 unit-dose packs) on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a prescription medication used for acute...
- The Defense Logistics Agency awarded a $3,413.91 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10s. This is a non-set-aside competitive award with a completion date of August 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is an acute treatment medication for migraine headaches, representing routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (Ubrogepant) 100 mg tablets, unit dose packages of 10, valued at $1,158.25 with a firm fixed price structure. This award, issued on July 21, 2025, represents a non-set-aside competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the contractor's distribution facility in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,048.62 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit-dose tablets) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with performance occurring at its corporate office location in the same city....
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging on July 29, 2025, with a ceiling value of $2,706.94 and ultimate completion date of July 30, 2025. UBRELVY is a calcitonin gene-related peptide (CGRP) receptor antagonist used for acute migraine treatment. This delivery order was competitively awarded without set-aside designation and carries firm fixed pricing. The contract is performed at...
- The Defense Logistics Agency awarded a delivery order valued at $29,146.75 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16-count unit dose packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, reflecting AmerisourceBergen's role as a...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1H7Delivery Order
The Defense Logistics Agency awarded a $2,347.18 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packages of 10. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 19, 2025. UBRELVY (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist used for acute migraine treatment, indicating this award supports the Department of Defense's pharmaceutical supply requirements for military healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle valued through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, supplying brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The company's status as a prime contractor on this significant IDC demonstrates its capability to meet extensive federal pharmaceutical supply needs through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/18/25 |